Payment overview · 2025
General Payments
$656.07
8 reported records · 5 companies
Healthcare provider profile · identity verified
John Koryakos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHOENIX, AZ · NPI 1598841884
Verified facts
What the public records show
CMS Open Payments records show John Koryakos, MD received $656.07 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 59.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $389.65 | 59.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.98 | 19.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.81 | 15.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.43 | 3.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.20 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $656.07 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $264.66 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $139.66 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 167 |
| Metformin Hcl | Metformin Hcl | 366 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 89 |
| Lisinopril | Lisinopril | 262 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 72 |
| Losartan Potassium | Losartan Potassium | 230 | 71 |
| Gabapentin | Gabapentin | 224 | 63 |
| Omeprazole | Omeprazole | 215 | 58 |
| Simvastatin | Simvastatin | 158 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 58 |
| Glipizide | Glipizide | 131 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 34 |
| Furosemide | Furosemide | 102 | 33 |
| Alendronate Sodium | Alendronate Sodium | 93 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 22 |
| Allopurinol | Allopurinol | 87 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 24 |
| Famotidine | Famotidine | 73 | 29 |
| Ibuprofen | Ibuprofen | 63 | 18 |
| Sertraline Hcl | Sertraline Hcl | 61 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 18 |
| Trazodone Hcl | Trazodone Hcl | 59 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 12 |
| Trulicity | Dulaglutide | 57 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Azithromycin | Azithromycin | 53 | 40 |
| Eliquis | Apixaban | 51 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 16 |
| Atenolol | Atenolol | 50 | 11 |
| Glimepiride | Glimepiride | 48 | 11 |
| Glipizide Er | Glipizide | 47 | 15 |
| Donepezil Hcl | Donepezil Hcl | 46 | 13 |
| Baclofen | Baclofen | 45 | 18 |
| Mirtazapine | Mirtazapine | 45 | 14 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 13 |
| Jardiance | Empagliflozin | 42 | 13 |
| Linzess | Linaclotide | 41 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Carvedilol | Carvedilol | 29 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 12 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Finasteride | Finasteride | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $656.07 · 8 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, LINZESS, Ozempic, SHINGRIX, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error